Literature DB >> 12109624

Impact of cervical lymph node dissection on serum TG and the course of disease in TG-positive, radioactive iodine whole body scan-negative recurrent/persistent papillary thyroid cancer.

A S Alzahrani1, H Raef, A Sultan, S Al Sobhi, S Ingemansson, M Ahmed, A Al Mahfouz.   

Abstract

In the management of papillary thyroid cancer (PTC), surgery is indicated for locoregional recurrent/persistent disease. In this study, we examined the effect of such surgery on serum TG and the course of the disease in 21 patients with PTC (mean age 38.5 yr), who after the initial surgery and radioactive iodine (RAI) ablation developed high TG (>10 ng/ml) and negative 123I whole body scan (DxWBS). All patients had neck persistent/recurrent PTC that was confirmed by ultrasound-guided fine needle aspiration. Prior to neck re-exploration, radiological studies (chest X-rays, CT scan of the chest, and fluoro-18-deoxyglucose positron emission tomography [FDG-PET]) showed no evidence of distant metastases. TG autoantibodies were negative in 19 patients. Second surgery consisted of unilateral (13 patients) or bilateral (8 patients) modified neck dissection. The mean+/-SE TG prior to neck re-exploration was 184.8+/-79.0 ng/ml and declined after surgery to 127.5+/-59.0 ng/ml (p=0.25). The corresponding TSH values were 150.6+/-23.0 and 143.4+/-20.0 mU/l, respectively (p=0.34). After a mean follow-up of 20.7+/-3 months, TG increased to 168+/-68.0 ng/ml. This increase, however, was NS (p=0.67). The corresponding TSH values were 143.4+/-20.0 and 132.0+/-22.0 mU/l (p=0.27). Following second surgery, only 4 patients achieved remission, the other 17 patients received one or more of the following therapies; RAI (10 patients), third surgery (5 patients), and/or external radiation (7 patients). Thirteen patients continued to have persistent disease and 4 patients showed progressive course of their disease (distant metastases or grossly palpable neck disease). In conclusion, second surgery for recurrent/persistent PTC leads to remission in only a minority of cases but the course of the disease tends to be stable in most cases.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12109624     DOI: 10.1007/BF03345495

Source DB:  PubMed          Journal:  J Endocrinol Invest        ISSN: 0391-4097            Impact factor:   4.256


  24 in total

1.  Detection of thyroglobulin in fine needle aspirates of nonthyroidal neck masses: a clue to the diagnosis of metastatic differentiated thyroid cancer.

Authors:  F Pacini; L Fugazzola; F Lippi; C Ceccarelli; R Centoni; P Miccoli; R Elisei; A Pinchera
Journal:  J Clin Endocrinol Metab       Date:  1992-06       Impact factor: 5.958

Review 2.  Papillary and follicular thyroid carcinoma.

Authors:  M J Schlumberger
Journal:  N Engl J Med       Date:  1998-01-29       Impact factor: 91.245

3.  Complementary role of whole body scan and serum thyroglobulin determination in the follow-up of differentiated thyroid carcinoma.

Authors:  G Ronga; A Fiorentino; G Fragasso; F M Fringuelli; V Todino
Journal:  Ital J Surg Sci       Date:  1986

4.  131I treatment of 131I negative whole body scan, and positive thyroglobulin in differentiated thyroid carcinoma: what is being treated?

Authors:  I R McDougall
Journal:  Thyroid       Date:  1997-08       Impact factor: 6.568

5.  Thyroglobulin determination, neck ultrasonography and iodine-131 whole-body scintigraphy in differentiated thyroid carcinoma.

Authors:  M Franceschi; Z Kusić; D Franceschi; L Lukinac; S Roncević
Journal:  J Nucl Med       Date:  1996-03       Impact factor: 10.057

6.  Superiority of iodine-123 compared with iodine-131 scanning for thyroid remnants in patients with differentiated thyroid cancer.

Authors:  S J Mandel; L K Shankar; F Benard; A Yamamoto; A Alavi
Journal:  Clin Nucl Med       Date:  2001-01       Impact factor: 7.794

7.  Prognostic value of [18F]fluorodeoxyglucose positron emission tomographic scanning in patients with thyroid cancer.

Authors:  W Wang; S M Larson; M Fazzari; S K Tickoo; K Kolbert; G Sgouros; H Yeung; H Macapinlac; J Rosai; R J Robbins
Journal:  J Clin Endocrinol Metab       Date:  2000-03       Impact factor: 5.958

8.  Diagnostic value of a single serum thyroglobulin determination on and off thyroid suppressive therapy in the follow-up of patients with differentiated thyroid cancer.

Authors:  F Pacini; R Lari; S Mazzeo; L Grasso; D Taddei; A Pinchera
Journal:  Clin Endocrinol (Oxf)       Date:  1985-10       Impact factor: 3.478

9.  Efficacy of sonographically guided biopsy of thyroid masses and cervical lymph nodes.

Authors:  G W Boland; M J Lee; P R Mueller; W Mayo-Smith; S L Dawson; J F Simeone
Journal:  AJR Am J Roentgenol       Date:  1993-11       Impact factor: 3.959

10.  Low levels of serum thyroglobulin after withdrawal of thyroid suppression therapy in the follow up of differentiated thyroid carcinoma.

Authors:  A J Brendel; B Lambert; M Guyot; R Jeandot; H Dubourg; P Roger; S Wynchauk; G Manciet; G Lefort
Journal:  Eur J Nucl Med       Date:  1990
View more
  9 in total

1.  Long-term course and predictive factors of elevated serum thyroglobulin and negative diagnostic radioiodine whole body scan in differentiated thyroid cancer.

Authors:  A S Alzahrani; G Mohamed; A Al Shammary; S Aldasouqi; S Abdal Salam; M Shoukri
Journal:  J Endocrinol Invest       Date:  2005-06       Impact factor: 4.256

2.  On-site ultrasound-guided localization for impalpable nodal recurrences in papillary thyroid carcinoma patients.

Authors:  Kuk-Jin Kim; Bup-Woo Kim; Yong Sang Lee; Hang-Seok Chang; Cheong Soo Park
Journal:  J Korean Surg Soc       Date:  2013-08-26

3.  Long-term efficacy of lymph node reoperation for persistent papillary thyroid cancer.

Authors:  Osama Al-Saif; William B Farrar; Mark Bloomston; Kyle Porter; Matthew D Ringel; Richard T Kloos
Journal:  J Clin Endocrinol Metab       Date:  2010-03-23       Impact factor: 5.958

4.  Preoperative neck ultrasonographic mapping for persistent/recurrent papillary thyroid cancer.

Authors:  Hussam M Binyousef; Ali S Alzahrani; Saif S Al-Sobhi; Suhaibani Hamed S Al; Mohammed A Chaudhari; Hussain M Raef
Journal:  World J Surg       Date:  2004-11       Impact factor: 3.352

5.  Radioguided occult lesion localization for locally recurrent thyroid carcinoma.

Authors:  Mehmet Ali Gulcelik; Niyazi Karaman; Lutfi Dogan; Ilgın Sahiner; Gokhan Giray Akgul; Yavuz Selim Kahraman; Gulin Ucmak Vural
Journal:  Eur Arch Otorhinolaryngol       Date:  2017-04-13       Impact factor: 2.503

Review 6.  2015 American Thyroid Association Management Guidelines for Adult Patients with Thyroid Nodules and Differentiated Thyroid Cancer: The American Thyroid Association Guidelines Task Force on Thyroid Nodules and Differentiated Thyroid Cancer.

Authors:  Bryan R Haugen; Erik K Alexander; Keith C Bible; Gerard M Doherty; Susan J Mandel; Yuri E Nikiforov; Furio Pacini; Gregory W Randolph; Anna M Sawka; Martin Schlumberger; Kathryn G Schuff; Steven I Sherman; Julie Ann Sosa; David L Steward; R Michael Tuttle; Leonard Wartofsky
Journal:  Thyroid       Date:  2016-01       Impact factor: 6.568

7.  Influence of TSH on uptake of [18F]fluorodeoxyglucose in human thyroid cells in vitro.

Authors:  J T Deichen; C Schmidt; O Prante; S Maschauer; T Papadopoulos; T Kuwert
Journal:  Eur J Nucl Med Mol Imaging       Date:  2004-01-14       Impact factor: 9.236

8.  Recombinant human thyroid stimulating hormone in 2008: focus on thyroid cancer management.

Authors:  Ann Gramza; Kathryn G Schuff
Journal:  Onco Targets Ther       Date:  2009-01-01       Impact factor: 4.147

9.  High rate of persistent/recurrent disease among patients with differentiated thyroid cancer in Saudi Arabia: factors affecting nonremission.

Authors:  Hussain Raef; Eman Alfadhli; Alya Al-Hajjaj; Usman H Malabu; Saif Al-Sobhi; Ayman Rifai; Abdulrahman Al Nuaim
Journal:  Ann Saudi Med       Date:  2008 Jul-Aug       Impact factor: 1.526

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.